Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 13/20 | 0.62 |
| ▸ | NPC1 | O15118 | 12/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | CASP3 | P42574 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.62 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.62 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.62 |
| ▸ | F7 | P08709 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.60 |
| ▸ | PKM | P14618 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8942820 | 0.97 | KDR (0.61) | KDRPDGFRBFGFR1RAB9ANPC1 | |
| SCHEMBL2784089 | 0.91 | RAB9A (0.67) | KDRPDGFRBFGFR1RAB9ANPC1 | |
| SCHEMBL31429678 | 0.83 | GUSB (0.65) | KDRPDGFRBFGFR1RAB9ANPC1 | |
| SCHEMBL10582358 | 0.83 | AMY1A (0.49) | KDRPDGFRBFGFR1RAB9ANPC1 | |
| SCHEMBL461968 | 0.82 | F7 (0.79) | RAB9ANPC1MEN1KMT2AUSP2 | |
| SCHEMBL29578227 | 0.82 | F7 (0.79) | RAB9ANPC1MEN1KMT2AUSP2 | |
| SCHEMBL14760241 | 0.81 | NPC1 (0.68) | KDRPDGFRBFGFR1RAB9ANPC1 | |
| SCHEMBL12471581 | 0.81 | AMY1A (0.66) | KDRPDGFRBFGFR1RAB9ANPC1 | |
| SCHEMBL30900824 | 0.81 | AMY1A (0.66) | KDRPDGFRBFGFR1RAB9ANPC1 | |
| SCHEMBL20677815 | 0.81 | NPC1 (0.75) | KDRPDGFRBFGFR1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2021-01-28 | — | — | US | disclosed |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-04-28 | — | — | US | disclosed |
| US-20190300480-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-10-03 | — | — | US | disclosed |
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-07-16 | — | — | US | disclosed |
| US-20170029372-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-02-02 | — | — | US | disclosed |
| US-20170029372-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-02-02 | — | — | US | disclosed |
| WO-2015154169-A1 | BINDING FUNCTION3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-10-15 | — | — | WO | disclosed |
| US-5501927-A | DISAZO OR TRISAZO DYES | FUJI XEROX CO., LTD. (JP) | 1996-03-26 | — | — | US | disclosed |
| US-4889924-A | ELECTROPHOTOGRAPHY; LIGHT SENSITIVE ELEMENTN IN PHOTORECEPTORS; DISAZO DYES | FUJI XEROX CO., LTD. (JP) | 1989-12-26 | — | — | US | disclosed |
| US-4206144-A | N,N-Dialkyl-N-aminoalkyl-N-(amino or nitro)phenylalkyl- and N-methyl-N-[3-(amino or nitro)phenoxy-2-hydroxy-1-propyl]-N,N-bis(3-aminopropyl)quaternary ammonium salts | STERLING DRUG INC. (US) | 1980-06-03 | — | — | US | disclosed |
| US-4146558-A | Azo dyestuff intermediate nitro- or aminobenzenes ring-substituted by a quaternized amine alkyl or amino-alkoxy group | STERLING DRUG INC. (US) | 1979-03-27 | — | — | US | disclosed |
| US-4103092-A | Water-soluble quaternary ammonium non-heterocyclic azo dyestuffs | STERLING DRUG INC. (US) | 1978-07-25 | — | — | US | disclosed |
| US-4065500-A | Water-soluble quaternary ammonium azo dyestuffs | STERLING DRUG INC. (US) | 1977-12-27 | — | — | US | disclosed |
| US-3996282-A | Water-soluble quaternary ammonium dyestuffs | STERLING DRUG INC. (US) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300480-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | KDR 902/4885PDGFRB 860/4885FGFR1 456/4885 |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | KLK3, SHBG, ACP3 | KDR 902/4885PDGFRB 860/4885FGFR1 456/4885 |
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | KLK3, SHBG, ACP3 | KDR 902/4885PDGFRB 860/4885FGFR1 456/4885 |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | KDR 902/4885PDGFRB 860/4885FGFR1 456/4885 |
| US-20170029372-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | KDR 902/4885PDGFRB 860/4885FGFR1 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.